Orpheus LLC is currently assessing the efficacy of our PD-L1 Pantid® in a mouse model. After demonstrating efficacy, we will scale up PD-L1 Pantid® production for pharmacokinetic and toxicological studies in preparation for a pre-IND meeting with the FDA.

We are also developing novel PD-L1 Pantid fusions for targeted immunomodulation and tolerogenesis induction, allowing the PD-L1 Pantid to target multiple autoimmune diseases.